急性髓系白血病异基因造血细胞移植后克隆性复发动态
该研究采用纠错型二代测序(NGS)对74例异基因造血细胞移植(alloHCT)后复发的急性髓系白血病(AML)患者进行 measurable residual disease(MRD)检测,分析复发前0.6至14个月采集的140份外周血样本。结果显示复发前6、3、1个月分别有10%、38%、64%的患者可检出至少1个MRD标志;每3个月监测可检出38%的复发,每月监测可检出64%。表观遗传修饰基因突变MRD阳性率更高且更稳定,信号基因突变领先时间更短。
要点
- 复发前1个月64%患者可检出MRD,前3个月为38%,前6个月为10%。
- 每月监测可检出64%的复发,每3个月监测可检出38%。
- 表观遗传修饰基因突变MRD阳性率更高且更稳定,信号基因突变领先时间更短。
核心结论
- 本研究为alloHCT后采用NGS进行MRD监测建立了框架,支持从诊断时已知的所有变异出发、每月对外周血进行监测。
研究设计与样本
- 采用纠错型二代测序(NGS)对74例alloHCT后复发的AML患者进行MRD检测,评估复发前0.6至14个月采集的140份外周血样本。
主要发现
- 复发前6、3、1个月分别有10%、38%、64%的患者可检出至少1个MRD标志。
- 每3个月监测可检出38%的复发,每月监测可检出64%的复发。
- 表观遗传修饰基因突变MRD阳性率更高且更稳定,信号基因突变领先时间更短。
- DTA(DNMT3A、TET2和ASXL1)与非DTA突变在alloHCT后随访期间显示相似的复发动力学。
临床怎么用
- 作者支持从诊断时已知的所有变异出发、每月对外周血进行NGS-MRD监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with acute myeloid leukemia (AML) who experience relapse following allogeneic hematopoietic cell transplantation (alloHCT) face unfavorable outcomes regardless of the chosen relapse treatment. Early detection of relapse at the molecular level by measurable residual disease (MRD) assessment enables timely intervention, which may prevent hematological recurrence of the disease. It remains unclear whether molecular MRD assessment can detect MRD before impending relapse and, if so, how long in advance. This study elucidates the molecular architecture and kinetics preceding AML relapse by using error-corrected next-generation sequencing (NGS) in 74 patients with AML relapsing after alloHCT, evaluating 140 samples from peripheral blood collected 0.6 to 14 months before relapse. At least 1 MRD marker became detectable in 10%, 38%, and 64% of patients at 6, 3, and 1 month before relapse, respectively. By translating these proportions into monitoring intervals, 38% of relapses would have been detected through MRD monitoring every 3 months, whereas 64% of relapses would have been detected with monthly intervals. The relapse kinetics after alloHCT are influenced by the functional class of mutations and their stability during molecular progression. Notably, mutations in epigenetic modifier genes exhibited a higher prevalence of MRD positivity and greater stability before relapse, whereas mutations in signaling genes demonstrated a shorter lead time to relapse. Both DTA (DNMT3A, TET2, and ASXL1) and non-DTA mutations displayed similar relapse kinetics during the follow-up period after alloHCT. Our study sets a framework for MRD monitoring after alloHCT by NGS, supporting monthly monitoring from peripheral blood using all variants that are known from diagnosis.
引用
- Wienecke CP, Heida B, Venturini L, et al. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood. 2024. PMID: 38669617. doi:10.1182/blood.2023022697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。